Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anlotinib Combined With Chemotherapy for the Treatment of HER2 Negative Advanced Breast Cancer Previously Treated With Anthracyclines and Taxanes: A Multicenter, Prospective, Observational Clinical Study

NCT05334147 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.

NCT NCT05334147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05334147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anlotinib Combined With Chemotherapy for the Treatment of HER2 Negative Advanced Breast Cancer Previously Treated With Anthracyclines and Taxanes: A Multicenter, Prospective, Observational Clinical Study
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Observational
Overall status
Unknown status
Start date
April 15, 2022
Completion date
September 1, 2025
Enrollment
315 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

her2-negative breast cancer